Dilated Cardiomyopathy Therapeutics Market Analysis Report (2022-2029)

Market Insights

The global dilated cardiomyopathy therapeutics market size was worth $YY.YY million in 2022 and is forecasted to reach $YY.YY million by 2029, at a CAGR of 4.0% during the forecast period 2022-2029. 

Dilated cardiomyopathy (DCM) is an abnormality of the heart muscle, usually starting in your heart's main pumping chamber (left ventricle). The ventricle becomes weakened and enlarged and can't pump blood. 

A common cause of heart failure is the heart's inability to supply the body with enough blood, and dilated cardiomyopathy also contributes to irregular heartbeats (arrhythmias), blood clots, or sudden death. People of all ages are affected by DCM, including infants and children, but it is most common in men ages 20 to 50.

Driving Factors Of The Market

The continuous research for the development of novel drugs, such as Ixmyelocel-T and ARRY-797, is expected to propel growth of the global dilated cardiomyopathy market.

With the rising demand for dilated cardiomyopathy treatment, several major companies have initiated to carry out clinical trials to develop drugs for dilated cardiomyopathy.

The prevalence of Heart artery disease is found majorly in Eastern Europe, followed by Central Asia and Central Europe, increasing rates were also seen in some parts of sub-Saharan Africa, the Middle East/North Africa region, and South Asia. These factors are driving the growth of the market in the forecast period.

Market Segmentation – By Drug Class- Angiotensin II Receptor Blockers

Losartan is an ARB that blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. It may induce a more complete inhibition of the renin-angiotensin system than ACE inhibitors, it does not affect the response to bradykinin, and it is less likely to be associated with cough and angioedema. It is used for patients unable to tolerate ACE inhibitors.

Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. It may induce more complete inhibition of renin-angiotensin system than ACE inhibitors, it does not affect response to bradykinin, and it is less likely to be associated with cough and angioedema. It is used in patients unable to tolerate ACE inhibitors.

Geographical Analysis- Asia Pacific

This region is expected to drive the market growth with increasing incidence of cardiovascular diseases and the increasing research and development in this region.

China is the most populated country and with increasing ageing population with rising heart disorders in the country are driving the demand for dilated cardiomyopathy therapeutic.

The government initiatives for the treatment of cardiovascular diseases is expected to boost the market growth in this region. For instance, Cardiovascular diseases (CVDs) are China's leading cause of death. The Chinese government has approved the Healthy China 2030 plan, which emphasizes the strategic importance of health in China's development.

Competitive Scenario

The market for dilated cardiomyopathy therapeutics is growing with leading players such as Pfizer Inc., AstraZeneca plc., Bristol-Myers Squibb Pharmaceuticals(MyoKardia), Novartis AG, ANI Pharmaceuticals, Inc., Endo International plc(Par Pharmaceutical), Arbor Pharmaceuticals, LLC., Amgen Inc., E. Merck KG, Advanz Pharma Corp.

These key market players are adopting various strategies such as mergers and acquisitions, product approvals, and agreements to increase product reach and strengthen their product portfolios, in order to enter or expand their business offerings and competitiveness in the dilated cardiomyopathy therapeutics market.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com